Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Visiongain Reports | Global Biotech Market Analysis and Forecasts, 2008-2023

Global Biotech Market Analysis and Forecasts, 2008-2023

- Includes Top 10 Therapy classes for biotech

- Also Top 10 products in the biotech sector

The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970’s. The leading biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in the world, with other biotechnology companies catching up. The global biotech drug market was worth over $75bn in 2007, with double-figure growth noticeably higher that that of the overall pharmaceutical market.

Over the period from 2008 to 2023, visiongain expects the healthcare biotechnological market to continue its strong growth, with exciting new developments both technologically and commercially. Increased R&D efforts, shorter approval times and innovative new treatments are aiding market growth. However, the two major threats the healthcare biotechnology sector faces in the coming years are the increasing threat of biogenerics and the difficulty in acquiring capital. Strategic partnerships will continue to be important to biotechnological drug development.

This brand new report - Global Biotech Market, 2008-2023- examines the healthcare biotech market critically, through comprehensive research and analysis. This report covers both the top ten therapy classes as well as the top ten leading pharmaceutical products in the biotech market in particular, as well as leading pipeline agents. Furthermore, visiongain applied techniques such as their in-house financial forecasting technology, SWOT analyses, R&D pipeline analysis and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

You will not find this information available anywhere else.

Why you should buy this report:

In particular, our Global Biotech Market, 2008-2023 report concentrates on the following essential aspects of that market, including the competitive environment for original branded products and biogenerics:

• Detailed analysis of the global biotech market, including an overall market sales forecast for 2008-2013, 2018 and 2023

• Sales forecasts for leading products and therapeutic areas for 2008-2013, 2018 and 2023

• Discussions of issues affecting the market segments, including SWOT analysis

• Drivers and opportunities in the biotech industry

• Restraints and threats facing the biotech industry

• Discussion of the leading companies and their strategy in the context of the market

• Pipeline developments and their implications for the future

• Strategic alliances and licensing.

There are significant financial benefits from a company’s having a portfolio of biotech drugs, especially in this very uncertain period, when technological and commercial change is accelerating. This realisation has caused the major pharmaceutical companies to establish themselves in the biotech market. At least half of the top ten pharmaceutical companies now have leading biotech drugs. Thinning developmental pipelines in small molecule agents can, in part, explain big pharma's embracing of the biotech market, forcing them to buy biotech firms with promising drugs in development. This report provides valuable commercial information on this exciting industry that no healthcare company should ignore.

Pricing:

Single user - password protected costs $2995.00

Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only

USD 5995. This is not suitable for library usage.

Allow your whole company to have access to this information for only USD 9,995. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only USD 13,995

26/8/08 Pages 150
Table of Contents

License

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions